# Liraglutide

Canonical source: https://retacompare.com/encyclopedia/liraglutide

Once-daily GLP-1 receptor agonist. Albumin binding via fatty acid extends in-vivo half-life.

Reference facts

Also known asVictoza, SaxendaCategoryGLP-1 & MetabolicMechanism of actionOnce-daily GLP-1 receptor agonist. Albumin binding via fatty acid extends in-vivo half-life.TargetsGLP-1RIndications under research or approvedType 2 Diabetes (Victoza), Chronic Weight Management (Saxenda)Regulatory status (reference entry)FDA-approved (Victoza 2010, Saxenda 2014)Half-life~13 hoursSequenceHAEGTFTSDVSSYLEGQAAKEFIAWLVRGRGSequence notes31-residue GLP-1(7-37) analog with Lys26 acylated by a γ-glutamyl-spaced C16 palmitic acid (mediates albumin binding).Molecular weight (Da)3751PDB accession4APDOriginator / sponsorNovo NordiskFirst reported2000OriginFirst once-daily GLP-1 analog, scaffold for the entire fatty-acid acylation strategy used by Semaglutide and Tirzepatide.
    Primary References

SCALE Obesity, NEJM 2015

LEADER cardiovascular outcomes, NEJM 2016


    Explore research articles about Liraglutide


    This is an educational reference, not medical advice. Research findings do not establish safety or efficacy for self-administration. Consult the primary sources for study populations, limitations, and current regulatory status.

## Sources

- SCALE Obesity, NEJM 2015: https://www.nejm.org/doi/full/10.1056/NEJMoa1411892
- LEADER cardiovascular outcomes, NEJM 2016: https://www.nejm.org/doi/full/10.1056/NEJMoa1603827